TY  - BOOK
AU  - Ho, An Thi Nhat
TI  - Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. [Review]
SN  - 1043-3074
PY  - 2019///
KW  - *Antineoplastic Agents/tu [Therapeutic Use]
KW  - *Carcinoma, Neuroendocrine/dt [Drug Therapy]
KW  - *Sorafenib/tu [Therapeutic Use]
KW  - *Thyroid Neoplasms/dt [Drug Therapy]
KW  - Antineoplastic Agents/ae [Adverse Effects]
KW  - Carcinoma, Neuroendocrine/sc [Secondary]
KW  - Humans
KW  - Sorafenib/ae [Adverse Effects]
KW  - Thyroid Neoplasms/sc [Secondary]
KW  - MedStar Union Memorial Hospital
KW  - Medicine
KW  - Journal Article
KW  - Review
N1  - Available online from MWHC library: 1996 - present
N2  - CONCLUSION: Our results show that sorafenib treatment has a modest effect and might be a candidate treatment in patients with metastatic MTCs who have failed other therapeutic regimens; Copyright (c) 2019 Wiley Periodicals, Inc; INTRODUCTION: The aim of this study is to investigate and summarize the treatment efficacy and adverse effects (AEs) of sorafenib in the treatment of metastatic medullary thyroid carcinomas (MTCs); METHODS: We included studies reporting the treatment efficacy or drug toxicity of sorafenib as a single therapeutic agent in MTCs. Pooled incidence and its 95% confidence interval (CI) for complete response, partial response (PR), stable disease (SD), and sorafenib-related AEs were calculated using random-effect model; RESULTS: Eight trials with 101 metastatic MTCs were included for meta-analyses. The overall PR and SD were 21% (95% CI = 9-33) and 58% (95% CI = 41-75), respectively. Hand-foot syndrome, diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension were the most commonly observed AEs
UR  - https://dx.doi.org/10.1002/hed.25832
UR  - https://dx.doi.org/10.1002/hed.25832
ER  -